The firm said that a strong start to the commercialization of its Liaison Plex platform also aided growth in its molecular diagnostics business.

Looking ahead, DiaSorin anticipates continued growth into fiscal year 2025, guiding for 7% CER growth with an estimated €20 million in COVID revenues, which translates to roughly 8% growth excluding ...

DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the ...

Yamamoto and Matano provide convincing evidence that a G63E/R CD8+ T-cell escape mutation in the accessory viral protein Nef promote the induction of neutralizing antibody (nAb) responses in rhesus ...

Yamamoto and Matano provide solid evidence that a G63E/R CD8+ T-cell escape mutation in the accessory viral protein Nef may facilitate the induction of neutralizing antibody (nAb) responses in rhesus ...